Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.67 Average Target Price from Brokerages

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.25.

Several research analysts have recently weighed in on AUPH shares. Leerink Partnrs downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $15.00 to $16.00 in a research report on Wednesday. Finally, Bloom Burton downgraded Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently made changes to their positions in AUPH. MAI Capital Management acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $39,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth approximately $48,000. Mackenzie Financial Corp acquired a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $86,000. State of Alaska Department of Revenue purchased a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $91,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Aurinia Pharmaceuticals in the second quarter worth $92,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ AUPH opened at $15.31 on Tuesday. The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals has a 12 month low of $6.55 and a 12 month high of $16.48. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 27.34 and a beta of 1.42. The business has a fifty day simple moving average of $13.46 and a 200-day simple moving average of $11.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 25.19% and a net margin of 29.28%.The firm had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Sell-side analysts predict that Aurinia Pharmaceuticals will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.